Introduction
Gliomas are the most common primary tumors of the central nervous system. [1] [2] [3] Among these tumors, the most frequent and malignant type is glioblastoma (GBM).
Glioblastomas have been described as rapidly growing tumors associated with necrosis and endothelial proliferation. These neoplasms are extremely resistant to treatment, including radiotherapy and/or chemotherapy, and patient median survival does not exceed 1 year. 4, 5 Although radiotherapy increases patient survival, this treatment is not curative because of tumor regrowth inside the irradiated tumor volume. [6] [7] [8] This might be explained by the fact that interactions between tumor and microenvironnement are involved in tumoral radioresistance through angiogenesis, 9 hypoxia 10 and immunosuppression. 11, 12 Another part of tumor radioresistance is due to intrinsic radioresistance of tumor cells themselves. A molecular analysis in tumor samples of basal activation of different signaling pathway potentially involved in radioresistance could be of clinical interest. Phosphatidyl-inositol 3-kinase (PI3K) / Protein Kinase B (Akt) and Janus Kinase (JAK) / Signal Transducer and Activator of Transcription (STAT) pathways serve to block apoptosis process, keeping cells alive in very toxic environments as chemotherapy or ionizing radiation (IR). 13, 14 In a bioclinical prospective study, Chakravarti et al. showed a significant correlation between the level of basal Akt phosphorylation and a poor prognosis in human glioma in a subset of patients treated by radiotherapy only. 15 Rahaman et al. reported experimental data demonstrating that inhibition of STAT3 signaling pathway was also associated with increased apoptosis and proliferation inhibition in malignant glioma. 16 The development of Akt and STAT3 inhibitors has been a goal of pharmaceutical companies since the discovery that these pathways are often activated in numerous human cancer such as melanoma, myeloma, brain cancer, breast cancer and ovarian cancer. 17, 18 Combining drugs with radiation is common in cancer treatment, and aim at achieving better therapeutic effects than with single-modality therapy. antibody failed to radiosensitize glioma cells. The radioresistance was evaluated using clonogenic cell survival assay and the basal level of activation of signaling pathways using Western blot. These data indicate that Akt intercept node could be a more relevant therapeutic target than STAT3 for radiosensitizing human malignant glioma. To date, little is known about direct relationship between Akt or STAT3 activation and tumor radioresistance. Our results showed significant correlation between basal Akt activation and Surviving Fraction at 2 Gy (SF2). Conversely, no such correlation was established between STAT3 activation and SF2 suggesting that Akt is a survival pathway associated with radioresistance. In our study, the most radioresistant glioma cell line was SF763, exhibiting an activation of both Akt and STAT3 signaling in basal conditions. SF763 was a good candidate to study effects of Akt or STAT3 down modulation on the radioresistance level. SF767 cell line presents only a high level of Akt and SNB19 cell line shows only an activation of STAT3 pathway so they are good models to study specific roles of respectively Akt and STAT3 inhibition in glioma radiosensitization.
Methods and Materials

Materials -
Results
Radiosensitivity analysis of human glioma cell lines by clonogenic cell survival -
Akt pathway down modulation and glioma radiosensitivity -Our results showed that
Akt pathway activation is closely related to human glioma radioresistance. Althought IR damages tumor cells through several mechanisms, IR is thought to kill cells primarily by causing DNA damage and, specifically, double strand breaks (DSBs). Prior to undergoing division, this leads to a DNA damage response to allow repair of the DNA damage. 30 The ability to repair is essential to cell survival because maintained DNA breaks induce apoptosis or senecence. 31 A recent study by Kao et al. reported that PI3K/Akt signaling pathway down modulation led to persistence of unrepaired DSBs induced by radiation in a human glioblastoma cell line (U251), demonstrating that this pathway can modulate DNA damage repair in response to radiation and may be involved in radiation therapy efficiency. 32 To explain this, one hypothesis could imply the DNA-dependent protein kinase (DNA-PK) which is one of the downstream targets of Akt signaling. 33 The greatest improvement in tumor control will also be through the understanding of stem cells radioresistance mechanisms. Down modulation of Akt signaling induced apoptosis, neurosphere formation suppression, and reduced motility and invasivness in brain tumor stem cells. 34 Interestingly, Akt down modulation sensitizes medullobastoma stem cells located in the perivascular region to radiation-induced apoptosis, suggesting that Akt inhibitors may be an effective anti-cancer stem cell therapy. 35 Here, we showed that Akt inhibitor IV was able to inhibit in a dose dependent manner whereas it could not radiosensitize glioma cell lines with PTEN wild type. 38 Re-establishment of PTEN was also a promising approach to radiosensitize glioma because PTEN is often mutated in these tumors. 32, 39 In contrast to PI-103 32 or Nelfinavir 39 , we reported in this work that Akt inhibitor IV radiosensitizes wild type PTEN glioma cells (SF763, SF767 38 ), but these two cell lines were selected for experiments because of their high level of radioresistance regardless their PTEN status.
STAT3 pathway down modulation and glioma radiosensitivity -JSI-124, acts as a highly selective inhibitor of the JAK/STAT3 signaling pathway. 22 Su et al have demonstrated that JSI-124 induced in glioma cells G (2) /M accumulation via downregulation of cyclin B1 and cdc2 expression. 40 Down modulation of STAT3 signaling using JSI-124 was also associated with a decrease in local immunosuppression in a murine intracranial model of glioma. 41 JSI-124 was recently shown to sensitize malignant glioma and medulloblastoma cells to temozolomide, 1,3-bis(2-chloroethyl)-1-nitrosourea, and cisplatin with a synergy between JSI-124 and cisplatin, 23 but to our knowledge, there is no study evaluating the ability of JSI-124 to alter cancer cell resistance to ionizing radiation. Here, we showed that JSI-124 alone was able to inhibit SF763 cells colony formation in a dose dependent manner, but that STAT3 down modulation, either using JSI-124 or anti-gp130 blocking antibody, did not modify SF763 cells sensitivity to ionizing radiation.
Despite the decrease of STAT3 pathway activation after anti-gp130 antibody exposure no radiosensitizing effect was observed in SNB19 cells. This is consistent with the absence of correlation between STAT3 activation and radioresistance level in the tested cell lines.
Moreover, a recent study reported that STAT3 can have a tumor-suppressive function that is regulated by the tumor suppressor PTEN. Nuclear constitutively activated form of Epidermal Growth Factor Receptor variant III (EGFRvIII) acts as a switch to convert this STAT3 from a tumor-suppressive to a pro-oncogenic protein. 42 Altogether our results with these last data support that STAT3 involvement in glioma radioresistance remains unclear and would depend on PTEN and EGFRvIII status in glioma cells.
In summary, the results of the present study and other reports 32, 38, 39 strongly suggest that Akt is a valid target for glioma cell radiosensitization. Our conclusions are different from those of de la Pena et al, who obtained no radiosensitization effect on glioma cells by treatment with perifosine, a drug that down regulate Akt phosphorylation. 43 Further experiments are needed to understand the link between PTEN, EGFRvIII and STAT3 status in regard to glioma radioresistance. These data indicate that Akt intercept node could be a more relevant therapeutic target than STAT3 for radiosensitizing human malignant glioma.
The PI3K/Akt pathway could be activated by numerous cytokines or growth factors.
We reported that among these activators, interleukin-6 (IL-6) gene amplification and overexpression were associated with poor survival in patients with malignant gliomas. 44 We have previously reported that interleukin-6 gene is amplified in SF763 but not in SF767 cell line. 45 PI3K/Akt could also be activated by EGFR which is often amplified in glioblastoma 46, 47 but EGFR status in these cell lines is unknown. Furthermore, receptor tyrosine kinase independent activation of the PI3K/Akt pathway is commonly observed in many cancers, and can occur through multiple mechanisms, such as mutation or amplification of PI3K gene, amplification of Akt gene, activation of an upstream oncogene (e.g., RAS), or mutation or decreased expression of the tumor suppressor PTEN. 48 Because of these multiple possibilities, instead of inhibiting a single cell surface receptor, down modulation of signal transduction through such an intercept node will be a more effective approach to block radioresistance. 49 The PI3K/Akt node could be a relevant therapeutic target to radiosensitize tumor cells by inhibiting both anti-apoptotic mechanisms and DNA damage repair after radiation. 
